Kazia Therapeutics Licenses AI-Driven SETDB1 Drug Discovery Platform from QIMR Berghofer
Kazia Therapeutics has licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, featuring an AI-integrated discovery engine and lead candidate MSETC aimed at overcoming tumor immune resistance.